ADRO - アデュロ・バイオテック (Aduro Biotech Inc.) アデュロ・バイオテック

 ADROのチャート


 ADROの企業情報

symbol ADRO
会社名 Aduro Biotech Inc (アデュロ・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アデュロ・バイオテク(Aduro BioTech Inc)は癌を含む各種の疾患の治療法の発見・開発・商業化に従事する免疫療法会社である。同社の製品候補は、ライブ、弱毒化、二重欠失(LADD)リステリアモノサイトゲネス、インターフェロン遺伝子経路経路活性化因子の刺激、及びB-選択モノクローナル抗体プラットフォームからのものであり、単一の薬剤として、または従来の治療法と組み合わせて、及び他の免疫療法として、自然免疫応答および適応免疫応答を刺激および/または調節するように設計されている。LADD技術プラットフォームは、中皮腫、卵巣癌、胃癌、肺癌および前立腺癌を含む複数の適応症の治療薬として開発されている。LADD製品候補は、中皮腫、卵巣癌および胃癌を含む複数の適応症の治療薬として開発されているCRS-207である。ADU-214とADU-741は、肺癌と前立腺癌の開発候補製品である。   アデュロ・バイオテックは、米国のバイオ医薬品会社。癌に対する免疫応答を刺激するために設計された技術プラットフォ―ムの開発に焦点を当て、腫瘍細胞の成長と普及を遅らせる、または排除するために患者の免疫系に影響を与える治療法の開発に従事。主要製品として、転移性膵臓癌と切除不能悪性胸膜中皮腫の治療用LADD製品であるCRS-207を提供する。   Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
本社所在地 740 Heinz Avenue Berkeley CA 94710 USA
代表者氏名 Stephen T. Isaacs スティーブン・T・アイザックス
代表者役職名 Chairman of the Board President and Chief Executive Officer
電話番号 +1 510-848-4400
設立年月日 2000年
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 162人
url www.aduro.com
nasdaq_url https://www.nasdaq.com/symbol/adro
adr_tso
EBITDA EBITDA(百万ドル) -100.80240
終値(lastsale) 6.09
時価総額(marketcap) 481473962.76
時価総額 時価総額(百万ドル) 515.46970
売上高 売上高(百万ドル) 16.81600
企業価値(EV) 企業価値(EV)(百万ドル) 226.35770
当期純利益 当期純利益(百万ドル) -93.14300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aduro BioTech Inc revenues decreased 4% to $9.3M. Net loss increased 11% to $45.9M. Revenues reflect Grant revenue decrease from $41K to $0K. Higher net loss reflects General and administrative. - other increase of 6% to $13.9M (expense) Stock-based Compensation increase of 15% to $5.3M (expense) Stock-based Compensation increase of 17% to $4M (expense).

 ADROのテクニカル分析


 ADROのニュース

   Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing  2020/10/05 13:00:00 GlobeNewswire
Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and…
   51 Biggest Movers From Yesterday  2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
   Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/08/03 20:05:00 GlobeNewswire
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing…
   Aduro Biotech's Shares March Higher, Can It Continue?  2020/05/26 12:11:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
   Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?  2020/05/25 16:00:05 Zacks Investment Research
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing  2020/10/05 13:00:00 GlobeNewswire
Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and…
   51 Biggest Movers From Yesterday  2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
   Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/08/03 20:05:00 GlobeNewswire
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing…
   Aduro Biotech's Shares March Higher, Can It Continue?  2020/05/26 12:11:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
   Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?  2020/05/25 16:00:05 Zacks Investment Research
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing  2020/10/05 13:00:00 GlobeNewswire
Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and…
   51 Biggest Movers From Yesterday  2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
   Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/08/03 20:05:00 GlobeNewswire
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing…
   Aduro Biotech's Shares March Higher, Can It Continue?  2020/05/26 12:11:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
   Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?  2020/05/25 16:00:05 Zacks Investment Research
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アデュロ・バイオテック ADRO Aduro Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)